Rifampicin reduces the levels of mycophenolic acid (the active
metabolite of mycophenolate) and increases the levels of the
metabolite associated with mycophe- nolate adverse effects.
Mycophenolate should be monitored for
efficacy and adverse effects if
rifampicin is given and the dose adjusted as required, both on starting and stopping
rifampicin.